Merger and Acquisition Scenario
Human Genome Sciences (HGSI) and Par Pharmaceutical Companies, Inc. (PRX)
| Date: | Aug 28, 2010 |
|---|---|
| Format: | HTML |
| Price: | $250.00 |
Abstract
Revere Data's Merger & Acquisition Scenario Report offers independent, objective and insightful analysis into a hypothetical combination of Human Genome Sciences (HGSI) with Par Pharmaceutical Companies, Inc. (PRX) . The Revere report begins by identifying Human Genome Sciences products that are either complementary or overlapping to Par Pharmaceutical Companies, Inc. products. Human Genome Sciences suppliers are then displayed alongside Par Pharmaceutical Companies, Inc. suppliers, with overlapping suppliers to both firms highlighted. Dependent suppliers to both companies are also displayed, including the percentage of dependent revenue if known. Top Human Genome Sciences customers and top Par Pharmaceutical Companies, Inc. customers, including overlapping customers, are also shown. The Revere report then includes key business relationship data in the area of strategic partnerships for each company. Additional content and features include Lines of Business Summaries, Product Summaries, Individual Human Genome Sciences Product Line and Par Pharmaceutical Companies, Inc. Product Line Details, Human Genome Sciences Earnings and Par Pharmaceutical Companies, Inc. Earnings Summaries, and pro forma financial statements. Revere Data Merger & Acquisition Scenario Reports are an essential source of competitive insight into an array of potential merger, acquisition, takeover, consolidation, rollup or other combination scenarios, with particular focus in the healthcare, biotechnology, information technology, finance and media sectors. Revere's extensive databases on key business relationships, product lines, focused sectors, and financial performance indicators provide a rich and integrated information source for investment banking, corporate finance, C-level executives, management consultants, marketing, and business intelligence professionals who want actionable answers and ideas in seconds.
Report Contents
- Summary
- Lines of Business Summary
- Product Summary
- Overlap & Complementary Sectors
- Sample Products in Similar Lines of Business
- Sample Products in Complementary Lines of Business
- Business Relationship Summary
- Top Key Suppliers
- Top Key Customers
- Key Financial Summary
- Individual Company Summary
- Focused Sector
- Revenue/Earnings Summary
- Business Description
- Product Summary
- Product Details
- Relationship Details
- Key Competitors
- Dependent Suppliers
- Key Customers
- Key Partners
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
Companies Mentioned in the Report
- Human Genome Sciences (HGSI) - Overview - Reports
- Par Pharmaceutical Companies, Inc. (PRX) - Overview - Reports
More Information:
Learn more about Merger and Acquisition Scenario Report.
Don't see the Scenario report you want? Request Merger and Acquisition Scenario Report »
Download Fact Sheet Merger and Acquisition Scenario (PDF)
Related Reports:
- Merger and Acquisition Scenario for Barr Pharmaceuticals, Inc. (BRL) and Human Genome Sciences (HGSI)
- Merger and Acquisition Scenario for Bristol Myers Squibb Co. (BMY) and Human Genome Sciences (HGSI)
- Merger and Acquisition Scenario for New River Pharmaceuticals, Inc. (NRPH) and Human Genome Sciences (HGSI)
- Merger and Acquisition Scenario for Chattem Inc. (CHTT) and Human Genome Sciences (HGSI)